{"originalText": "，缘于入院前4月余于我院诊断为直肠癌，于2016-01-21在全麻上行腹腔镜上直肠癌姑息性切除术DIXON，，术后病理：（201602459）1、（直肠），：肠溃疡型管状腺癌II级，侵及外膜层。手术标本下、上切端及另送（下切端）、（上切端）均未见癌浸润。找到肠周淋巴结0/6个，未见癌转移。肠周脂肪组织中找到12枚癌结节。2、（肠系膜上动脉根部淋巴结），：送检为纤维、脂肪及脉管组织。3、（盆壁结节），：送检为癌结节。，免疫组化：KI67（50%+），CK7（-），CK20（+++），VILLIN（++++），CDX-2（+++），CD56（-），MLH1（+），MSH2（+），PMS2（-），MSH-6（+）。，微卫星稳定性：MSI-L。，病理：（MM20160170）该病例检测到KRAS基因12号密码子G12D突变。，病理：(MM20160171)该病例未检测到BRAF基因V600E突变。术后给予对症、营养支持等治疗，恢复可。于2016.03.19,2016.5.4予“伊立替康240MGD1+卡培他滨片1500MGBIDD1-14”方案化疗，辅以保胃、保肝、增强免疫等，未见明显化疗副反应。出院后无腹痛、腹胀，无呕血、黑便，无发热、寒战等。此次为行上一周期化疗再次就诊我院，门诊拟直肠癌术后化疗收入院。下次出院以来精神、睡眠、饮食可，大小便正常，体重较前无明显变化。", "entities": [{"label_type": "疾病和诊断", "overlap": 0, "start_pos": 15, "end_pos": 18}, {"label_type": "手术", "overlap": 0, "start_pos": 35, "end_pos": 53}, {"label_type": "解剖部位", "overlap": 0, "start_pos": 74, "end_pos": 76}, {"label_type": "疾病和诊断", "overlap": 0, "start_pos": 79, "end_pos": 90}, {"end_pos": 134, "label_type": "解剖部位", "overlap": 0, "start_pos": 129}, {"label_type": "解剖部位", "overlap": 0, "start_pos": 145, "end_pos": 146}, {"end_pos": 175, "label_type": "解剖部位", "overlap": 0, "start_pos": 164}, {"end_pos": 445, "label_type": "药物", "overlap": 0, "start_pos": 441}, {"end_pos": 458, "label_type": "药物", "overlap": 0, "start_pos": 453}, {"end_pos": 482, "label_type": "解剖部位", "overlap": 0, "start_pos": 481}, {"end_pos": 485, "label_type": "解剖部位", "overlap": 0, "start_pos": 484}, {"end_pos": 507, "label_type": "解剖部位", "overlap": 0, "start_pos": 506}, {"end_pos": 510, "label_type": "解剖部位", "overlap": 0, "start_pos": 509}, {"label_type": "疾病和诊断", "overlap": 0, "start_pos": 547, "end_pos": 552}]}
